2. Immunology/Inflammation
  3. CD47
  4. Magrolimab

Magrolimab  (Synonyms: 莫洛利单抗; Hu5F9-G4)

目录号: HY-P99029 纯度: 99.92%
COA

摩尔计算器

Magrolimab (Hu5F9-G4) 是一种人源化抗 CD47 抗体。 Magrolimab 可以阻断 CD47 的 “不要吃我” 信号，从而促进巨噬细胞介导的吞噬作用。Magrolimab 在恶性骨肿瘤和乳腺癌中具有抗肿瘤活性。

MCE 的所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

我们将采用定制合成服务的方式为您快速提供所需产品和技术服务

CAS No. : 2169232-81-7

1.  客户无需承担相应的运输费用。

2.  同一机构（单位）同一产品试用装仅限申领一次，同一机构（单位）一年内

     可免费申领三个不同产品的试用装。

3.  试用装只面向终端客户。

规格 价格 是否有货 数量
1 mg ￥2300
In-stock
5 mg ￥5500
In-stock
10 mg ￥8000
In-stock
50 mg   询价  
100 mg   询价  

* Please select Quantity before adding items.

Customer Review

Magrolimab 相关抗体

Top Publications Citing Use of Products

MCE 顾客使用本产品发表的 1 篇科研文献

  • 生物活性

  • 纯度 & 产品资料

  • 参考文献

生物活性

Magrolimab (Hu5F9-G4) is a humanized anti-CD47 antibody. Magrolimab can block the "don't eat me" signal of CD47, thereby promoting macrophage mediated phagocytosis. Magrolimab has antitumor activity in malignant bone tumors and breast cancer[1][2][3].
同型

Human IgG4 kappa
推荐同型对照抗体
种属

Chimeric; Humanized

体外研究
(In Vitro)

Magrolimab (10 μg/mL, 24 h) 可以促进肿瘤相关巨噬细胞对卵巢或乳腺肿瘤细胞的吞噬作用[3]。

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Magrolimab 相关抗体:
体内研究
(In Vivo)

Magrolimab (12-100 μg; 每天 1 次; 10 天; 腹腔注射) 在尤因肉瘤小鼠中具有抗肿瘤活性[1]。
Magrolimab (250 μg; 每两天 1 次; 7 周; 腹腔注射) 与曲妥珠单抗 (HY-P9907) 联合使用可在乳腺癌小鼠中消除 HER2 阳性乳腺癌细胞并克服曲妥珠单抗耐受性[2]。

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: Humanized and non-humanized ES xenograft NSG-SGM3 mice[1].
Dosage: 12-100 μg
Administration: Intraperitoneal injection (i.p.); once daily; 10 days
Result: Inhibited tumor growth and lung metastasis, and prolonged animal survival time.
Animal Model: 4-8 weeks old NSG female breast cancer mouse model[2].
Dosage: 250 μg
Administration: Intraperitoneal injection (i.p.); once every two days; 7 weeks (implanted GFP/luciferase BT474 cells into the left mammary fat pad of female mice)
Result: Restricted the Growth of HER2 ADCC-Tolerant Tumors.
Clinical Trial
CAS 号
性状

液体

颜色

Colorless to light yellow

中文名称

莫洛利单抗
运输条件

Shipping with dry ice.
储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.
Format
  • Human IgG4 kappa
Biological Activity
  • Flow cytometry analysis of Jurkat cells labelling CD47 with Magrolimab at 100nM (Red). Goat anti human IgG Fc(Alexa Fluor488) was used as the secondary antibody at 1/400 dilution. Isotype control - human IgG (Blue). Unlabeled control - Unlabelled cells (Gray).
纯度 & 产品资料

纯度: 99.92%

COA (264 KB) SDS-PAGE (65 KB) SEC-HPLC (159 KB)

抗体抑制剂使用指南 (1152 KB)
参考文献

Magrolimab 相关分类

  • 摩尔计算器

  • 稀释计算器

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

质量   浓度   体积   分子量 *
= × ×

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

浓度 (start) × 体积 (start) = 浓度 (final) × 体积 (final)
× = ×
C1   V1   C2   V2
Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

Magrolimab2169232-81-7Hu5F9-G4莫洛利单抗CD47Cluster of Differentiation 47MER6OA3antibodybreast cancerbone tumourInhibitorinhibitorinhibit

您最近查看的产品:

Your information is safe with us. * Required Fields.

   产品名称：

  

* 需求量：

* 客户姓名：

 

* Email：

* 电话：

 

* 公司或机构名称：

   留言给我们：

Bulk Inquiry

Inquiry Information

产品名称：
Magrolimab
目录号：
HY-P99029
需求量：

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

   产品名称：

  

* Lot #：

* 客户姓名：

 

* Email：

   电话：

 

* 部门：

* 公司或机构名称：

 

   留言给我们：

Request for HNMR Report

We have received your request and will respond to you as soon as possible.

嗨！很高兴为您提供帮助！

尊敬的 MCE 客户您好，
请您选择所在区域，我们将转接对应客服为您服务！

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

热 A B C F G H J L N Q S T X Y Z